Lamivudin Sandoz (Lamivudine)

Lamivudin Sandoz is a nucleoside reverse transcriptase inhibitor used in viral disease management.

• HIV infection: reduces viral load and helps restore immune function when used in combination antiretroviral therapy.
• Chronic hepatitis B infection: suppresses HBV DNA replication and improves liver enzyme profiles.
• HIV‑1 infection in treatment‑experienced patients: provides an alternative NRTI backbone for regimen optimisation.

• Lamivudine is phosphorylated intracellularly to its active triphosphate form, which competes with natural deoxycytidine triphosphate for incorporation into viral DNA by HIV reverse transcriptase. Incorporation results in chain termination, halting viral DNA synthesis and thereby inhibiting replication of HIV and hepatitis B virus.

Lamivudin Sandoz may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Headache: transient cranial discomfort.
• Fatigue: general tiredness.
• Diarrhea: loose stools.
• Insomnia: difficulty sleeping.
• Elevated liver enzymes: mild hepatic enzyme changes.

Serious or Rare Side Effects

• Lactic acidosis: severe metabolic disturbance requiring immediate medical attention.
• Hepatotoxicity: significant liver injury, potentially leading to jaundice.
• Pancreatitis: inflammation of the pancreas with abdominal pain.
• Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Peripheral neuropathy: nerve pain or tingling sensations.
• Anemia: reduction in red blood cell count.

Use of Lamivudin Sandoz requires careful clinical monitoring to minimise risks.

• Renal function: assess creatinine clearance before initiation and periodically thereafter.
• Hepatic function: monitor liver enzymes and bilirubin levels during therapy.
• Hypersensitivity: discontinue if signs of allergic reaction such as rash or swelling appear.
• Pregnancy: evaluate risk‑benefit ratio; use only if clearly needed.
• Concomitant medications: review for potential interactions that may affect drug levels.
• Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Lamivudin Sandoz can interact with several agents, altering efficacy or safety.

Major Interactions (Avoid)

• Didanosine: combined use increases risk of pancreatitis.
• Stavudine: may heighten peripheral neuropathy.
• Tenofovir: concurrent use can exacerbate renal toxicity.

Moderate Interactions (Monitor Closely)

• Rifampin: induces metabolism, potentially lowering lamivudine concentrations.
• Antacids containing aluminum or magnesium: may reduce absorption if taken simultaneously.
• Alcohol: can worsen hepatic side effects; monitor liver function.